These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12203098)

  • 21. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
    Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
    Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF).
    Akasheh M; Eastwood D; Vesole DH
    Bone Marrow Transplant; 2003 Jan; 31(2):113-6. PubMed ID: 12621492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
    Small EJ; Sacks N; Nemunaitis J; Urba WJ; Dula E; Centeno AS; Nelson WG; Ando D; Howard C; Borellini F; Nguyen M; Hege K; Simons JW
    Clin Cancer Res; 2007 Jul; 13(13):3883-91. PubMed ID: 17606721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
    Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
    J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
    Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
    Jakubowski AA; Bajorin DF; Templeton MA; Chapman PB; Cody BV; Thaler H; Tao Y; Filippa DA; Williams L; Sherman ML; Garnick MB; Houghton AN
    Clin Cancer Res; 1996 Feb; 2(2):295-302. PubMed ID: 9816172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys.
    Hotchkiss CE; Hall PD; Cline JM; Willingham MC; Kreitman RJ; Gardin J; Latimer A; Ramage J; Feely T; DeLatte S; Tagge EP; Frankel AE
    Toxicol Appl Pharmacol; 1999 Jul; 158(2):152-60. PubMed ID: 10406930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients with advanced colorectal cancer.
    Fiedler W; Krüger W; Laack E; Mende T; Vohwinkel G; Hossfeld DK
    Oncol Rep; 2001; 8(2):225-31. PubMed ID: 11182031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of subcutaneous granulocyte colony-stimulating factor injectate volume on drug efficacy, site complications, and client comfort.
    Comley AL; DeMeyer E; Adams N; Edwards C; Gilman LC; Good A; Mathews M; Mindemann LA; Wertheim S; Josey L; Phillips JM
    Oncol Nurs Forum; 1999; 26(1):87-94. PubMed ID: 9921571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia.
    Bernard F; Thomas C; Emile JF; Hercus T; Cassinat B; Chomienne C; Donadieu J
    Blood; 2002 Apr; 99(7):2615-6. PubMed ID: 11895804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice.
    Iversen PO; Lewis ID; Turczynowicz S; Hasle H; Niemeyer C; Schmiegelow K; Bastiras S; Biondi A; Hughes TP; Lopez AF
    Blood; 1997 Dec; 90(12):4910-7. PubMed ID: 9389708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukine studies move forward.
    Vazquez E
    Posit Aware; 1999; 10(4):29. PubMed ID: 11366803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.